Holi Raises €2.8M to Scale Digital Obesity Clinic
💎 Holi Raises €2.8M to Scale AI-Powered Obesity Treatment Platform Across Southern and Eastern Europe
Polish startup Holi has raised 12.5 million PLN (~€2.8 million) in a seed funding round led by 4growth VC, with participation from German funds YZR Capital and Heartfelt Capital, alongside notable business angels. The round will fund international expansion and development of Holi’s tech-enabled, data-driven obesity treatment platform that integrates medical expertise, behavioral therapy, and GLP-1 pharmacotherapy.
The fresh capital will support Holi’s ambitions to expand into fast-growing telemedicine markets in Southern and Eastern Europe, where private healthcare is increasingly in demand. Holi’s goal is to become the go-to digital clinic for metabolic health by combining automation, AI-based monitoring, and real-time therapeutic intervention.
Subscribe to Startup Digest to stay ahead with the latest news, investments, and must-attend events.
Tackling One of the World’s Most Pressing Health Crises
Obesity is now recognized by the World Health Organization as one of the greatest global health challenges, with over 800 million individuals living with obesity and nearly 2 billion classified as overweight. Holi addresses this with a hybrid care model that merges clinical precision with digital engagement.
Through its mobile app and online dashboard, Holi provides patients access to a team of doctors, psychodieticians, psychologists, and physiotherapists, while supporting them with personalized treatment plans and GLP-1 pharmacotherapy (including drugs like Ozempic and Wegovy). The platform delivers coordinated care that addresses both the physiological and behavioral drivers of obesity.
Results-Driven Technology and Clinical Outcomes
Holi’s approach leads to an average weight loss of 17% within 12 months—approximately 1.5x more effective than standalone GLP-1 drug therapy. This is achieved through algorithmic dosage optimization, behavioral habit tracking, and smart nudges designed to improve patient engagement and reduce dropout rates.
“We’re building a solution that leads to sustained metabolic health improvements,” said Paweł Seweryn, founder and CEO of Holi. “Obesity treatment requires continuity of care and a multidisciplinary approach. The funding allows us to internationalize our model and enhance our tech stack.”
Holi also claims to reduce GLP-1-related medication costs by up to 50%, thanks to its data-driven optimization protocols—making long-term therapy more affordable and accessible.
AI Meets Clinical Insight
At the core of Holi’s innovation is a real-time analytics engine that monitors patient data and flags moments when human intervention is most effective. “The future of obesity treatment is hybrid,” noted Jan Kundziołka, Holi co-founder and Head of Product. “AI provides precision. Human experts deliver results. Our platform ensures doctors intervene when they’ll have the greatest impact.”
This balance between automation and medical oversight supports better outcomes, higher adherence, and scalable care delivery—a critical need in a global health system already strained by comorbidities and treatment costs linked to obesity.
Why Investors Are Betting on Holi
For lead investor 4growth VC, Holi represents the rare convergence of clinical efficacy, technological scalability, and market readiness. “Obesity remains one of the most underappreciated health needs globally,” said Krzysztof Bachta, Managing Partner at 4growth VC. “Holi’s care model is virtual, scalable, and delivers medically proven results at a price point that works for both patients and payers.”
Markus Feuerecker, co-founder and managing partner at YZR Capital, echoed this sentiment, noting Holi’s rapid clinical and operational progress since their initial investment. “Holi is scaling fast while maintaining medical integrity, which is rare in this space. That’s why we significantly increased our stake in this round.”
Market Potential and Future Outlook
The European obesity treatment market is estimated at €40–50 billion, with private patient spending accelerating due to the mainstream adoption of GLP-1 medications like Ozempic, Wegovy, and Mounjaro. Holi is well-positioned to capitalize on this trend by offering a full-stack solution that blends prescription therapeutics with lifestyle interventions.
As consumer interest in metabolic health grows, and payers search for cost-effective chronic care models, Holi’s platform may serve as a blueprint for digital-first, high-impact chronic disease management. The company is currently operating in Poland and plans to enter multiple European markets over the next 18 months.
With AI-enabled healthtech startups on the rise, Holi joins a growing list of Polish digital health pioneers—including Docplanner, Infermedica, and Telemedi—who are reshaping the future of care delivery through automation, personalization, and access.
